Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from genetically defined diseases, particularly those with high unmet medical needs. The company focuses on rare diseases and employs a proprietary product engine to systematically identify and validate cellular drug targets. This technology aims to modulate gene expression to address the root causes of these diseases. Fulcrum Therapeutics collaborates with other industry leaders, such as MyoKardia, to discover novel targeted therapies for genetic cardiomyopathies. The company operates in the biopharmaceutical market, serving patients, healthcare providers, and research institutions. Its business model revolves around developing and commercializing innovative therapies, generating revenue through product sales, partnerships, and licensing agreements.

Keywords: biopharmaceutical, genetically defined diseases, rare diseases, drug discovery, gene expression, proprietary technology, collaboration, cardiomyopathies, clinical-stage, innovative therapies.